Free Trial
TSE:OGI

Organigram (OGI) Stock Price, News & Analysis

Organigram logo
C$1.82 -0.01 (-0.55%)
As of 04:00 PM Eastern

About Organigram Stock (TSE:OGI)

Key Stats

Today's Range
C$1.76
C$1.85
50-Day Range
C$1.81
C$2.50
52-Week Range
C$1.76
C$3.95
Volume
418,843 shs
Average Volume
302,177 shs
Market Capitalization
C$224.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$3.67
Consensus Rating
Buy

Company Overview

Organigram Inc. is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.

Organigram Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

OGI MarketRank™: 

Organigram scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Organigram has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Organigram has only been the subject of 1 research reports in the past 90 days.

  • Read more about Organigram's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Organigram is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Organigram is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Organigram has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Organigram has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for OGI.
  • Dividend Yield

    Organigram does not currently pay a dividend.

  • Dividend Growth

    Organigram does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for OGI.
  • News Sentiment

    Organigram has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Organigram this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for OGI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Organigram to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Organigram insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    31.32% of the stock of Organigram is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 8.37% of the stock of Organigram is held by institutions.

  • Read more about Organigram's insider trading history.
Receive OGI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organigram and its competitors with MarketBeat's FREE daily newsletter.

OGI Stock News Headlines

Alliance Global Partners Estimates Organigram Q3 Earnings
Q3 EPS Estimates for Organigram Reduced by Atb Cap Markets
Why Buffett and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
Haywood Reaffirms Their Buy Rating on OrganiGram Holdings (OGI)
See More Headlines

OGI Stock Analysis - Frequently Asked Questions

Organigram's stock was trading at C$2.30 at the beginning of 2025. Since then, OGI stock has decreased by 20.9% and is now trading at C$1.82.
View the best growth stocks for 2025 here
.

Shares of OGI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Organigram investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Innovative Industrial Properties (IIPR), Aurora Cannabis (ACB), Canopy Growth (WEED), Aphria (APHA) and NVIDIA (NVDA).

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Cannabis
CIK
N/A
Fax
N/A
Employees
987
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$3.67
High Stock Price Target
C$4.35
Low Stock Price Target
C$3.15
Potential Upside/Downside
+101.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
C$-57,230,259.02
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$180.58 million
Cash Flow
C$0.47 per share
Book Value
C$2.85 per share

Miscellaneous

Free Float
N/A
Market Cap
C$224.85 million
Optionable
Not Optionable
Beta
1.13
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (TSE:OGI) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners